Evaluation of the diagnostic test for rapid detection of covid-19 antigen (Panbio Covid rapid test) in primary care
Copyright © 2021 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved..
OBJECTIVE: COVID-19 infection requires early diagnosis, with PCR being the gold standard test. The protocols advocate the use of rapid antigenic tests that require evaluation in actual clinical practice. The objective was to evaluate the diagnostic test for rapid antigen detection, Panbio Covid rapid test, compared with PCR, in patients with symptoms of 5 or less days of evolution and with a high-suspicion of infection by COVID-19 in a health center.
MATERIALS AND METHODS: 103 patients over 14 years of age who attended an urban health center located in the Usera District of Madrid, with high-suspicion of COVID-19 infection, in the first 5 days of evolution from the onset of symptoms during the month of November 2020.
INTERVENTIONS: diagnostic tests for COVID-19 are performed: antigen and PCR.
RESULTS: The prevalence of the disease was 24.3% according to the PCR test and 17.5% according to the rapid antigenic test. The sensitivity was 72% (95% CI: 54.3-89.6%). The specificity was 100%. The positive and negative predictive values were 100% and 91.8% respectively. In the bivariate analysis, there was no relationship between symptoms and the presence of disease, except for myalgias (p=0.030). The multivariate analysis found a relationship between cough, dyspnea, fever, myalgia, anosmia/ageusia, and ocular symptoms and the presence of disease.
CONCLUSIONS: The sensitivity and specificity for the Panbio rapid antigen test are similar to other studies performed in primary care. In high-prevalence of disease and with highly suspected symptoms, positive test results can be considered definitive, but negative results will require confirmation. Myalgia, fever, dyspnea, anosmia/ageusia, and ocular symptoms may be more related to the presence of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Semergen - 47(2021), 8 vom: 28. Nov., Seite 508-514 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Evaluación de la prueba diagnóstica de detección rápida de antígeno de covid-19 (Panbio Covid rapid test) en atención primaria |
|---|
| Beteiligte Personen: |
Cortés Rubio, J A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atención Primaria de Salud |
|---|
| Anmerkungen: |
Date Completed 26.11.2021 Date Revised 07.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semerg.2021.06.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33073105X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33073105X | ||
| 003 | DE-627 | ||
| 005 | 20231225211919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.semerg.2021.06.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM33073105X | ||
| 035 | |a (NLM)34531125 | ||
| 035 | |a (PII)S1138-3593(21)00175-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Cortés Rubio, J A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the diagnostic test for rapid detection of covid-19 antigen (Panbio Covid rapid test) in primary care |
| 246 | 3 | 3 | |a Evaluación de la prueba diagnóstica de detección rápida de antígeno de covid-19 (Panbio Covid rapid test) en atención primaria |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.11.2021 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a OBJECTIVE: COVID-19 infection requires early diagnosis, with PCR being the gold standard test. The protocols advocate the use of rapid antigenic tests that require evaluation in actual clinical practice. The objective was to evaluate the diagnostic test for rapid antigen detection, Panbio Covid rapid test, compared with PCR, in patients with symptoms of 5 or less days of evolution and with a high-suspicion of infection by COVID-19 in a health center | ||
| 520 | |a MATERIALS AND METHODS: 103 patients over 14 years of age who attended an urban health center located in the Usera District of Madrid, with high-suspicion of COVID-19 infection, in the first 5 days of evolution from the onset of symptoms during the month of November 2020 | ||
| 520 | |a INTERVENTIONS: diagnostic tests for COVID-19 are performed: antigen and PCR | ||
| 520 | |a RESULTS: The prevalence of the disease was 24.3% according to the PCR test and 17.5% according to the rapid antigenic test. The sensitivity was 72% (95% CI: 54.3-89.6%). The specificity was 100%. The positive and negative predictive values were 100% and 91.8% respectively. In the bivariate analysis, there was no relationship between symptoms and the presence of disease, except for myalgias (p=0.030). The multivariate analysis found a relationship between cough, dyspnea, fever, myalgia, anosmia/ageusia, and ocular symptoms and the presence of disease | ||
| 520 | |a CONCLUSIONS: The sensitivity and specificity for the Panbio rapid antigen test are similar to other studies performed in primary care. In high-prevalence of disease and with highly suspected symptoms, positive test results can be considered definitive, but negative results will require confirmation. Myalgia, fever, dyspnea, anosmia/ageusia, and ocular symptoms may be more related to the presence of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atención Primaria de Salud | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Diagnostic tests | |
| 650 | 4 | |a Prevalence | |
| 650 | 4 | |a Prevalencia | |
| 650 | 4 | |a Primary health care | |
| 650 | 4 | |a Pruebas diagnósticas | |
| 650 | 4 | |a Sensibilidad y especificidad | |
| 650 | 4 | |a Sensitivity and specificity | |
| 700 | 1 | |a Costa Zamora, M P |e verfasserin |4 aut | |
| 700 | 1 | |a Canals Aracil, M |e verfasserin |4 aut | |
| 700 | 1 | |a Pulgar Feio, M |e verfasserin |4 aut | |
| 700 | 1 | |a Mata Martínez, A |e verfasserin |4 aut | |
| 700 | 1 | |a Carrasco Munera, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Semergen |d 1998 |g 47(2021), 8 vom: 28. Nov., Seite 508-514 |w (DE-627)NLM095511652 |x 1578-8865 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:8 |g day:28 |g month:11 |g pages:508-514 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semerg.2021.06.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2021 |e 8 |b 28 |c 11 |h 508-514 | ||